Real-world evidence (RWE) is increasingly important to clinicians, regulators and payers Regional and local registries are a valuable source of RWE The large Corrona RA US registry has revealed information revenant to clinical practice (e.g. non-adhearance, effectiveness and safety of biologics,...Learn More
8-13 November, 2019 | Atlanta, GA
American College of Rheumatology Annual Meeting
20-24 March, 2020 | Denver, CO
American Academy of Dermatology Annual Meeting
2-5 May, 2020 | Chicago, IL
Digestive Disease Week Annual Meeting
3-6 June, 2020 | Frankfurt, Germany
EULAR: Annual European Congress of Rheumatology 2020
News
Jun 16 2017 - 8:00am
News
Jun 13 2017 - 8:00am
Corrona, a provider of U.S. disease registries, has enrolled the first patient in its novel inflammatory bowel disease (IBD) registry, launched in May 2017. This is the first national registry to collect data from patients with ulcerative colitis, Crohn’s disease and other IBDs. Corrona joined the...Learn More
News
Jun 1 2017 - 1:15pm
SOUTHBOROUGH, Mass., June 1, 2017 /PRNewswire — Corrona, a nationwide provider of disease registries, announced that the first patient has been enrolled in its groundbreaking Inflammatory Bowel Disease (IBD) Registry. No national registry presently collects data from patients with inflammatory...Learn More
News
Jan 3 2017 - 8:00am
by Nancy Walsh Senior Staff Writer, MedPage Today: Dimitrios A. Pappas, MD , of Columbia University and the Corrona registry, talked to MedPage Today about a recent study evaluating whether or not the use of glucocorticoids influenced the time to initiating biologic therapy among patients with...Learn More
News
Dec 13 2016 - 8:15am
by Nancy Walsh Senior Staff Writer, MedPage Today: As treatments for rheumatoid arthritis have multiplied, questions about their optimal use remain. Two experts reported on new findings for the interleukin-6 receptor inhibitor tocilizumab (Actemra) in an online supplement to Arthritis &...Learn More
News
Dec 9 2016 - 8:30am
In this video interview, Dr. Leslie Harrold discussed her presentation regarding the impact of Rituxan on PROs in patients with RA. Dr. Harrold was quoted as saying, “What we did was we identified patients who were starting rituximab and looked at how they did at one year out using patient-reported...Learn More